Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

NCT03896945 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
136
Enrollment
INDUSTRY
Sponsor class

Stopped Based on the Interim Analysis outcome and recommendation by the DMC, Otsuka approved termination of the study based on futility.

Conditions

Interventions

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.